IL18 and type 2 diabetes mellitus: GSK1070806, a neo-IgG1 mAb that neutralizes IL-18, has been tested in a pilot trial in type 2 diabetes and kidney transplantation [80], and a corresponding RCT based on genomic detection of IL-18 in IBD is warranted.